Home » Stocks » Karuna Therapeutics

Karuna Therapeutics, Inc. (KRTX)

Stock Price: $82.50 USD 2.53 (3.16%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.20B
Revenue (ttm) n/a
Net Income (ttm) -42.52M
Shares Out 26.62M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $82.50
Previous Close $79.97
Change ($) 2.53
Change (%) 3.16%
Day's Open 80.03
Day's Range 79.55 - 83.31
Day's Volume 97,595
52-Week Range 12.48 - 152.00

More Stats

Market Cap 2.20B
Enterprise Value 1.83B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 26.62M
Float 17.42M
EPS (basic) -0.38
EPS (diluted) -1.90
FCF / Share -1.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.55M
Short Ratio 7.49
Short % of Float 8.93%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.78
Revenue n/a
Operating Income -46.64M
Net Income -42.52M
Free Cash Flow -39.64M
Net Cash 365.12M
Net Cash / Share 13.72
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -12.75%
ROE -18.95%
ROIC -23.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 11
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(50.52% upside)
Current: $82.50
Target: 124.18
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-45.41-14.51-4.81
Net Income-43.96-17.51-6.03
Shares Outstanding11.96--
Earnings Per Share-3.68-4,378,000.00-
Operating Cash Flow-30.92-15.38-4.03
Capital Expenditures-0.12-0.13-0.01
Free Cash Flow-31.04-15.51-4.04
Cash & Equivalents39014.011.94
Total Debt0.212.5211.66
Net Cash / Debt38911.49-9.72
Book Value390-29.92-13.37
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Karuna Therapeutics, Inc.
Country United States
Employees 19
CEO Steven Marc Paul

Stock Information

Ticker Symbol KRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KRTX
IPO Date June 28, 2019


Karuna Therapeutics, a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.